Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.39
- Piotroski Score 6.00
- Grade Overweight
- Symbol (JAZZ)
- Company Jazz Pharmaceuticals plc
- Price $110.89
- Changes Percentage (0.64%)
- Change $0.7
- Day Low $110.06
- Day High $112.83
- Year High $137.39
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $200.00
- High Stock Price Target $250.00
- Low Stock Price Target $169.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.83
- Trailing P/E Ratio 23.2
- Forward P/E Ratio 23.2
- P/E Growth 23.2
- Net Income $414.83 M
Income Statement
Quarterly
Annual
Latest News of JAZZ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Utah Jazz pick up 5th-year option on coach Will Hardy's contract
Utah Jazz extended coach Will Hardy's contract through 2026-27 season, showing confidence in his leadership despite a rebuilding phase. Known for player development and communication skills, Hardy's c...
By AP NEWS | 1 day ago -
Lady Gaga: Harlequin review - Joker companion album does jazz standards with a gaudy grin
Lady Gaga's new jazz album "Harlequin" is a departure from her pop sound, featuring covers and original songs inspired by her role as Harley Quinn. While the album showcases Gaga's versatility, some s...
By The Guardian | 2 days ago -
Jack DeJohnette, One of Jazz's Great Drummers, Has a Surprise
Renowned musician Jack DeJohnette, known for his drumming skills, will perform a rare solo concert on piano at 82. He gained fame playing with icons like Miles Davis and Keith Jarrett, showcasing his ...
By The New York Times | 4 days ago
